FDMT vs T · rev $37.0K vs P/E 7.4, rev $125.65B
4D Molecular Therapeutics Inc (FDMT) versus AT&T Inc. (T) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
AT&T Inc. (T) is a telecom services company listed on NYSE. It is led by John Stankey.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported T revenue for 2025-12-31 was $125.65B. Net income was $21.95B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. T currently screens at market cap $155.92B and trailing P/E 7.4.
FDMT currently screens at market cap $518.1M. T currently screens at market cap $155.92B and trailing P/E 7.4.
Not investment advice. Open the FDMT and T stock pages for the full models.
Not investment advice.